본문으로 건너뛰기
← 뒤로

Therapeutic targeting of FZD receptor proteins with biologics in cancer.

1/5 보강
Drug discovery today 📖 저널 OA 13.8% 2023: 0/1 OA 2024: 0/1 OA 2025: 2/8 OA 2026: 2/19 OA 2023~2026 2026 Vol.31(2) p. 104621
Retraction 확인
출처

Hmila I, Katanaev VL

📝 환자 설명용 한 줄

Wnt signaling plays key roles in the initiation, progression, and therapy resistance of various cancers.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Hmila I, Katanaev VL (2026). Therapeutic targeting of FZD receptor proteins with biologics in cancer.. Drug discovery today, 31(2), 104621. https://doi.org/10.1016/j.drudis.2026.104621
MLA Hmila I, et al.. "Therapeutic targeting of FZD receptor proteins with biologics in cancer.." Drug discovery today, vol. 31, no. 2, 2026, pp. 104621.
PMID 41655894 ↗

Abstract

Wnt signaling plays key roles in the initiation, progression, and therapy resistance of various cancers. No drugs targeting this pathway are currently available, and several candidates have failed because they affected healthy tissues such as bone and intestine. It is necessary, therefore, to develop efficient and safe Wnt pathway inhibitors that act selectively on tumors. The targeting of individual FZD receptor proteins that initiate Wnt pathways is a promising approach to the development of selective inhibitors. In this review, we summarize the physiological and pathological roles of each of ten FZDs and describe diverse selective biologics that have been developed to target them. Antibodies, designer proteins, peptides, nanobodies, and aptamers are being studied for their potential as selective, efficient, and safe anti-Wnt treatments that could be used to combat specific cancers and other pathologies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반